Eli Lilly is raising the list price of its diabetes drug Mounjaro in the U.K. starting in September. The company reached an agreement with the U.K. government to increase the list price while ensuring access for patients covered under the NHS. The current price in the UK ranges from £92 to £122 a month, but will increase to between £133 and £330 starting Sept. 1.

The list price increase will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity or as a treatment for type 2 diabetes. Eli Lilly supports the Trump administration’s goal of more fairly sharing the costs of breakthrough medical research across developed countries. U.S. prescription drug prices are 2-3 times higher on average than other developed nations.

Eli Lilly’s announcement comes as the industry prepares for Trump’s planned tariffs on pharmaceuticals imported into the U.S. The company opposes the tariffs, stating they will raise costs, limit patient access, and undermine American leadership. In recent months, Eli Lilly has announced plans to invest in U.S. manufacturing sites, aligning with Trump’s goal of bringing manufacturing back to the U.S.

Read more at CNBC: Eli Lilly hikes price of Mounjaro in UK amid Trump pressure